Introduction
============

Several studies of critically ill patients have suggested an association of the D/D genotype of the insertion/deletion (I/D) angiotensin-converting enzyme (ACE) polymorphism with poor outcome probably by enhancing the inflammatory response and leading to a procoagulant state. Our aim was to evaluate the effect of both the ACE I/D polymorphism and its gene product, on the clinical outcome of critically ill septic patients.

Methods
=======

The study cohort included 186 consecutive Caucasian patients with sepsis, severe sepsis or septic shock. Epidemiological, clinical data and co-morbidities along with severity scores were recorded. Measurements of serum ACE activity and genotyping for ACE I/D polymorphism were carried out in all patients. The primary outcomes were the 28-day and 90-day mortalities; secondary outcomes included the number of days without renal or cardiovascular failure, and ventilation-free days over the 28-day period following the study enrollment. One hundred and eighty healthy blood donors were genotyped and used as controls.

Results
=======

The genotype distribution in the patients\' group was comparable with that observed in controls (*P*= 0.45). ACE I/D polymorphism and circulating ACE levels were not associated with mortality (*P*\> 0.05) or with secondary outcomes including ventilation-free days and days without cardiovascular or renal failure among septic critically ill patients (*P*\> 0.05). See Figure [1](#F1){ref-type="fig"}.
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Conclusions
===========

Neither the ACE I/D polymorphism nor the serum ACE levels seem to be significant prognostic factors of the outcome of sepsis in critically ill patients.
